MaxCyte公司近日宣布,已与基因泰克(Genentech)达成一项多平台技术许可合作协议,旨在加速细胞疗法的研发进程。此次合作将利用MaxCyte领先的细胞工程平台技术,支持基因泰克在多个治疗领域的创新细胞疗法开发项目。
MaxCyte公司近日宣布,已与基因泰克(Genentech)达成一项多平台技术许可合作协议,旨在加速细胞疗法的研发进程。此次合作将利用MaxCyte领先的细胞工程平台技术,支持基因泰克在多个治疗领域的创新细胞疗法开发项目。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.